Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25465411 | 0.83 | GABRA1 (0.38) | GABRA1TSHRGABRG2GABRB3GABRB2 | |
| SCHEMBL15887374 | 0.81 | GABRA1 (0.36) | GABRA1TSHRGABRG2GABRB3GABRB2 | |
| SCHEMBL10122079 | 0.79 | GABRA1 (0.38) | GABRA1TSHRGABRG2GABRB3GABRB2 | |
| SCHEMBL9962275 | 0.79 | GABRA1 (0.38) | GABRA1TSHRGABRG2GABRB3GABRB2 | |
| SCHEMBL20275976 | 0.76 | TSHR (0.37) | ALDH1A1TSHRALOX15ALOX12 | |
| SCHEMBL23980767 | 0.74 | GABRA1 (0.33) | ALDH1A1GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL10522329 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TSHRCA1CA2CYP1A2 | |
| SCHEMBL18970159 | 0.73 | GABRA1 (0.44) | ALDH1A1GABRA1TSHRGABRB2ALOX15 | |
| SCHEMBL29801762 | 0.73 | GABRA1 (0.46) | GABRA1TSHRGABRG2GABRB3GABRB2 | |
| SCHEMBL5503549 | 0.73 | GABRA1 (0.46) | GABRA1TSHRGABRG2GABRB3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| CN-220989713-U | Crystallization desolventizing rectifying device for liquid compound | 威海市文登区检验检测中心 | 2024-05-24 | — | — | CN | disclosed |
| CN-117298637-A | Crystallization desolventizing rectifying device for liquid compound and control method thereof | 威海市文登区检验检测中心 | 2023-12-29 | — | — | CN | disclosed |
| EP-4269399-A1 | FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| EP-0862544-B1 | PROCESS FOR PURIFYING A 2,6-DIALKYLPHENOL | ALBEMARLE CORP (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-0862544-A1 | PROCESS FOR PURIFYING A 2,6-DIALKYLPHENOL | ALBEMARLE CORPORATION (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5705039-A | CONTINUOUS DISTILLATION IN OXIDATION RESISTANT ENVIRONMENT | ALBEMARLE CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5705039-A | CONTINUOUS DISTILLATION IN OXIDATION RESISTANT ENVIRONMENT | ALBEMARLE CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997015542-A1 | PROCESS FOR PURIFYING A 2,6-DIALKYLPHENOL | ALBEMARLE CORPORATION (US) | 1997-05-01 | — | — | WO | disclosed |
| US-5591311-A | 2,6-DIISOPROPYLPHENOL | ALBEMARLE CORPORATION (US) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | ALDH1A1 1978/4885GABRA1 554/4885TSHR 1134/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | ALDH1A1 3182/4885GABRA1 318/4885TSHR 80/4885 |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | ALDH1A1 3352/4885GABRA1 299/4885TSHR 82/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885GABRA1 4260/4885TSHR 2250/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885GABRA1 4260/4885TSHR 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.